Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

Exclusion Criteria

• •Women who are pregnant or nursing. Female participants must have a negative urine pregnancy test at screening.
• •DSM-IV defined substance or alcohol dependence within the 2 months preceding the start of the trial
• •Treatment with a monoamine oxidase inhibitor (e.g., tranylcypromine, phenelzine, isocarboxazid) within 2 weeks of starting the trial
• •Patients considered at high risk for suicide or violence
• •Patients with history of or symptoms on systems review consistent with clinically significant and currently relevant hematologic, renal, hepatic, gastrointestinal, endocrine, pulmonary, dermatologic, oncologic or neurologic (including seizures or epilepsy) disease
• •Patients with a history of or symptoms on systems review consistent with significant cardiovascular disease, bypass surgery, or concurrent cardiovascular disease, including uncontrolled hypertension, hypotension, congestive heart failure, angina pectoris, or recent (within last 6 months) myocardial infarction
• •Use of any investigational drug within 4 weeks before screening
• •History of hypersensitivity or other intolerable adverse effects to modafinil
• •Patients who experience severe sleep disturbances from modafinil